Replimune Group, Inc. - REPL
About Gravity Analytica
Recent News
- 06.06.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06.06.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06.06.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06.05.2025 - 2025 Jefferies Global Healthcare Conference
- 06.05.2025 - 2025 Jefferies Global Healthcare Conference
- 06.01.2025 - Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- 06.01.2025 - Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- 05.29.2025 - Replimune to Present at the 2025 Jefferies Global Healthcare Conference
- 05.29.2025 - Replimune to Present at the 2025 Jefferies Global Healthcare Conference
- 05.22.2025 - Fourth Quarter & Fiscal 2025 Earnings Conference Call
Recent Filings
- 05.23.2025 - S-8 Securities to be offered to employees in employee benefit plans
- 05.23.2025 - S-3 Registration statement under Securities Act of 1933
- 05.23.2025 - S-3 Registration statement under Securities Act of 1933
- 05.22.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
- 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
- 05.22.2025 - 8-K Current report
- 05.22.2025 - EX-99.1 EX-99.1